Literature DB >> 15668825

[Pharmacological cardioversion of atrial fibrillation].

J R Ehrlich1, S H Hohnloser.   

Abstract

Atrial fibrillation is a very common rhythm disorder that can be therapeutically reverted into sinus rhythm by means of pharmacological or electrical cardioversion. This article reviews options for drug therapy and tries to elucidate the mechanisms of AF termination by antiarrhythmics. We will explain the clinical basis of different therapeutic approaches and review the efficacy of selected substances according to recent clinical studies. Finally, we will focus on some important aspects of anticoagulation in the setting of pharmacological cardioversion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668825     DOI: 10.1007/s00392-005-0166-9

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  59 in total

1.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation.

Authors:  L Yue; J Feng; R Gaspo; G R Li; Z Wang; S Nattel
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

2.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.

Authors:  R H Falk; A Pollak; S N Singh; T Friedrich
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

3.  Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.

Authors:  L Bianconi; M Mennuni; V Lukic; A Castro; M Chieffi; M Santini
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

4.  Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.

Authors:  F D Murgatroyd; S M Gibson; X Baiyan; S O'Nunain; J D Poloniecki; D E Ward; M Malik; A J Camm
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

5.  Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation.

Authors:  Y J Chen; S A Chen; M S Chang; C I Lin
Journal:  Cardiovasc Res       Date:  2000-11       Impact factor: 10.787

6.  Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.

Authors:  I A Khan
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

Review 8.  Sotalol.

Authors:  S H Hohnloser; R L Woosley
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

9.  Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.

Authors:  J Wang; G W Bourne; Z Wang; C Villemaire; M Talajic; S Nattel
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  3 in total

1.  Simultaneous angiographic imaging of ipsilateral pulmonary veins for catheter ablation of atrial fibrillation.

Authors:  B Strohmer; C Schernthaner; M Pichler
Journal:  Clin Res Cardiol       Date:  2006-09-08       Impact factor: 5.460

2.  Pharmacological and ablative hybrid therapy of atrial fibrillation. Long-term effect on quality of life and arrhythmia-related symptoms.

Authors:  H Bielik; J Schrickel; N Shlevkov; A Yang; J O Schwab; A Bitzen; B Lüderitz; T Lewalter
Journal:  Z Kardiol       Date:  2005-09

3.  Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.

Authors:  L Obergassel; T Lawrenz; F H Gietzen; F Lieder; C Leuner; H Kuhn; C Stellbrink
Journal:  Clin Res Cardiol       Date:  2006-03-21       Impact factor: 6.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.